Ginkgo biloba extract EGb761 in dementia: a meta-analysis of randomised controlled trials
Tan MS, Yu JT, Tan CC, Wang HF, Meng XF, Tan L
Published in Journal of Alzheimer's Disease
Methodology
Meta-analysis of 9 randomised controlled trials of EGb761 in patients with Alzheimer's disease, vascular or mixed dementia
Key Findings
EGb761 at 240 mg/day produced modest improvement in cognition and activities of daily living in patients with dementia, with clearer effects in those with neuropsychiatric symptoms.
Conclusions
EGb761 240 mg/day may produce small benefits in established dementia, in contrast with negative prevention trials.
Limitations
Several trials were industry-sponsored; heterogeneity in dementia subtypes and outcome scales.
Supplements Studied
EGb761 at 240 mg per day was able to stabilise or slow decline in cognition, function, behaviour and global change at 22-26 weeks in cognitive impairment and dementia.
Outcomes Measured
EGb761 at 240 mg per day stabilised or slowed decline in cognition and function in patients with cognitive impairment.
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.